Maxim Pharmaceuticals Announces Robert L. Zerbe Nominated to Its Board of Directors

15-Jan-2003

Maxim Pharmaceuticals, Inc. announced that it has nominated Robert L. Zerbe, M.D. to serve as an independent member of its Board of Directors.

Dr. Zerbe, 52, is the Chief Executive Officer and Founder of QuantRx Pharmaceuticals, a private biopharmaceutical company. Until 2000, Dr. Zerbe was employed by Pfizer as its Senior Vice President of Global Research and Development and Director of Development Operations. Dr. Zerbe also held senior positions in pharmaceutical development at Warner-Lambert and Eli Lilly. During his career in the United States and Europe, Dr. Zerbe has been involved in leadership of the development of a number of the biggest and most successful pharmaceutical drugs, including Prozac(R), Lipitor(R), Neurontin(R), Humulin(R), Humatrope(R), Zyprexa(R), Raloxifene(R), Humalog(R), and Gemzar(R).

Dr. Zerbe is a physician licensed in Indiana and Michigan with training in Internal Medicine and Endocrinology at Indiana University and advanced training in Neuroendocrinology at the National Institute of Mental Health. Dr. Zerbe earned his M.D. with distinction at the Indiana University School of Medicine in Indianapolis. He is the author of numerous research publications in endocrinology, neuroendocrinology and pharmacology, and has significant experience in clinical research and development, clinical trial design and management, and regulatory affairs.

https://www.chemeurope.com/en/news/18545/maxim-pharmaceuticals-announces-robert-l-zerbe-nominated-to-its-board-of-directors.html